PFG Advisors Increases Stock Position in IQVIA Holdings Inc. (NYSE:IQV)

PFG Advisors raised its position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 24.8% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 7,571 shares of the medical research company's stock after buying an additional 1,503 shares during the period. PFG Advisors' holdings in IQVIA were worth $1,335,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of IQV. Sowell Financial Services LLC bought a new position in IQVIA in the first quarter valued at approximately $305,000. Mather Group LLC. boosted its stake in IQVIA by 83.5% in the first quarter. Mather Group LLC. now owns 769 shares of the medical research company's stock valued at $136,000 after acquiring an additional 350 shares during the last quarter. Park Avenue Securities LLC boosted its stake in IQVIA by 40.4% in the first quarter. Park Avenue Securities LLC now owns 5,425 shares of the medical research company's stock valued at $956,000 after acquiring an additional 1,562 shares during the last quarter. Wealth Enhancement Advisory Services LLC boosted its stake in IQVIA by 34.5% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 13,259 shares of the medical research company's stock valued at $2,338,000 after acquiring an additional 3,398 shares during the last quarter. Finally, Blair William & Co. IL boosted its stake in IQVIA by 42.0% in the fourth quarter. Blair William & Co. IL now owns 5,742 shares of the medical research company's stock valued at $1,128,000 after acquiring an additional 1,699 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company's stock.

Analyst Ratings Changes

A number of brokerages have recently weighed in on IQV. William Blair reissued an "outperform" rating on shares of IQVIA in a research report on Wednesday. Mizuho lifted their price target on shares of IQVIA from $190.00 to $225.00 and gave the company an "outperform" rating in a research note on Friday. Hsbc Global Res downgraded shares of IQVIA from a "strong-buy" rating to a "hold" rating in a report on Friday, April 25th. Cowen reaffirmed a "buy" rating on shares of IQVIA in a report on Wednesday. Finally, UBS Group upped their price objective on shares of IQVIA from $185.00 to $225.00 and gave the stock a "buy" rating in a research report on Wednesday. Seven investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $228.62.

IQVIA Stock Down 0.8%

NYSE IQV traded down $1.65 on Friday, hitting $199.17. 2,138,911 shares of the company were exchanged, compared to its average volume of 2,043,734. The company has a market cap of $33.86 billion, a PE ratio of 28.82, a PEG ratio of 2.29 and a beta of 1.30. IQVIA Holdings Inc. has a 12 month low of $134.65 and a 12 month high of $252.88. The stock has a fifty day moving average of $155.96 and a 200-day moving average of $170.53. The company has a current ratio of 0.84, a quick ratio of 0.82 and a debt-to-equity ratio of 2.45.

IQVIA (NYSE:IQV - Get Free Report) last released its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share for the quarter, beating analysts' consensus estimates of $2.77 by $0.04. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The firm had revenue of $4.02 billion for the quarter, compared to analyst estimates of $3.96 billion. During the same period last year, the firm earned $2.64 earnings per share. The business's quarterly revenue was up 5.3% compared to the same quarter last year. As a group, analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.